Diabetes Forum 2013 - Managing comorbid liver disease in patients with type 2 diabetes

Endocrinology
Curriculum:
Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control
Credits:
0.75 AMA PRA Category 1 Credits
Launch Date:
13-Aug-13
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Anp, Clinicians (Md, Do, Pa) Who Make Treatment Decisions For People With Diabetes And Related Conditions

Relevant Terms:

Non-Alcoholic Fatty Liver Disease, Diabetes, Dyslipidemia, Hypertension, Coronary Artery Disease, Non-Alcoholic Steatohepatitis

Jody Dushay, MD, MMSc

Jody Dushay, MD, MMSc
Instructor in Medicine
Harvard Medical School
Division of Endocrinology
Beth Israel Deaconess Medical Center
Boston, MA

Jody Dushay is an Instructor in Medicine at Harvard Medical School and an attending physician in the Division of Endocrinology at the Beth Israel Deaconess Medical Center. She received her MD degree from Harvard Medical School in 2000 and her MMSc from the Harvard/MIT Clinical Investigator Training Program in 2009.
 
Dr. Dushay focuses her clinical research and clinical care in the areas of obesity, diabetes, and nonalcoholic fatty liver disease. She is currently conducting investigator-initiated clinical research studies examining mechanisms of weight loss with GLP-1 agonism as well as the physiology and regulation of a novel metabolic protein, fibroblast growth factor 21, in humans.
 
Dr. Dushay is Assistant Program Director of the Harvard Thorndike Clinical Research Center and a Vice Chair of the BIDMC Institutional Review Board. She is a member of the ADA and the Obesity Society and she has been an ad hoc reviewer for Obesity, Metabolism and Diabetes Care.
1. Demonstrate how key confounding conditions that commonly accompany diabetes (aging, renal dysfunction, coronary artery disease, elevated liver enzymes/fatty liver, & obesity) will impact design and management of a glycemic control program.
2. Demonstrate the ability to adjust glycemic treatments to optimize control and also compensate for common confounding comorbidities

Planning Committee
 
Richard S. Beaser, MD
Associate Clinical Professor of Medicine, Harvard Medical School
Medical Executive Director, Professional Education
Joslin Diabetes Center
Boston, MA
  • Dr. Beaser is a consultant for CeQur, LTD and serves on the Academic Advisory Board at Bristol-Myers Squibb and AstraZeneca LP
Julie A. Brown, CCMEP
Director, Professional Education
Joslin Diabetes Center
Boston, MA
  • Ms. Brown Ms. Brown has no relevant financial relationships
James Neighbours, MEd
Associate Director, Education and Technology Services
Professional Education
Joslin Diabetes Center
Boston, MA
  • Mr. Neighbours has no relevant financial relationships
Eyiuche Okeke, MD
Instructor in Medicine, Harvard Medical School
Outcomes Investigator, Department of Professional Education
Staff Endocrinologist
Joslin Diabetes Center
Boston, MA
  • Dr. Okeke has no relevant financial relationships
Ruth Hertzman-Miller, MD, MPH
Director, Medical Programs
Professional Education
Joslin Diabetes Center
Boston, MA
  • Dr. Hertzman-Miller has no relevant financial relationships
Karen J. Kuc, MPH
Assistant Director, Grants and Projects
Professional Education
Joslin Diabetes Center
Boston, MA
  • Ms. Kuc has no relevant financial relationships
 
CME Advisory Committee
 
Richard S. Beaser, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Medical Executive Director, Professional Education
Joslin Diabetes Center
Boston, MA
 
Julie A. Brown
Director
Professional Education
Joslin Diabetes Center
Boston, MA
 
Enrique Caballero, MD
Director, Medical Affairs
Professional Education
Director, Latino Diabetes Initiative
Joslin Diabetes Center
Boston, MA
 
Jerry Cavallerano, OD, PhD
Optometrist
Beetham Eye Institute
Joslin Diabetes Center
Boston, MA
 
A. Patrick Egan, MD
Family Practice
Internal Medicine Specialist
Dorchester House Multi-Service Center
Boston, MA
 
Ann E. Goebel-Fabbri, PhD
Instructor in Psychiatry
Harvard Medical School
Psychologist
Behavioral and Mental Health Unit
Joslin Diabetes Center
Boston, MA
 
Osama Hamdy, MD, PhD, FACE
Assistant Professor of Medicine
Harvard Medical School
Medical Director, Obesity Clinical Program
Joslin Diabetes Center
Boston, MA
 
Karen Kuc
Assistant Director
Professional Education
Joslin Diabetes Center
Boston, MA
     
James Neighbours, MEd
Associate Director
Education Design
Professional Education
Joslin Diabetes Center
Boston, MA
 
Robert C. Stanton, MD
Associate Professor of Medicine
Harvard Medical School
Chief of Nephrology
Joslin Diabetes Center
Boston, MA
 
Howard Wolpert, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Insulin Pump Program
Senior Physician
Joslin Diabetes Center
Boston, MA
 
 
DISCLOSURE POLICY STATEMENT
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.
 
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
 
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.
 
 
Faculty
 
Dr. Jody Dushay has no relevant financial relationships.

Dr. Osama Hamdy,* Medical Director, Obesity Clinical Program, Joslin Diabetes Center, is a consultant for Abbott Nutrition and Merck & Co., Inc.

Dr. Lyle D. Mitzner has no relevant financial relationships.

Dr. Mark E. Molitch receives grant/research support from Sanofi USA, LLC; is a consultant for Abbott Laboratories and Janssen Pharmaceuticals, Inc.-; receives grant/research support from and is a consultant for Lilly USA, LLC, Novartis Pharmaceuticals Corporation, and Novo Nordisk Inc.; and holds stock in Amgen Inc. and Merck & Co., Inc.

Dr. Medha Munshi receives grant/research support from Sanofi USA, LLC. Dr. Munshi's spouse is a consultant for Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.
 
*Also a member of the Advisory Committee

 
Planning Committee
 
Dr. Richard S. Beaser, Medical Executive Director, Professional Education, Joslin Diabetes Center, is a consultant for AstraZeneca/Bristol-Myers Squibb Company and CeQur Ltd LTD.**
 
Julie A. Brown, Director, Professional Education, Joslin Diabetes Center, is a consultant for AstraZeneca/Bristol-Myers Squibb Company.**
 
Ruth Hertzman-Miller, MD, MPH, Director, Medical Programs, Professional Education, Joslin Diabetes Center has no relevant financial relationships.
 
Karen J. Kuc, MPH, Assistant Director, Grants and Projects, Joslin Diabetes Center, has no relevant financial relationships.**
 
James E. Neighbours, Associate Director, Education Design, Professional Education, Joslin Diabetes Center, has no relevant financial relationships. **
 
Dr. Okeke, outcomes investigator, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.  
 
**Also a member of the Advisory Committee
 
 
CME Advisory Committee
 
Dr. Richard S. Beaser,* Medical Executive Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
 
Julie A. Brown,* Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
 
Dr. Enrique Caballero, Director, Medical Affairs, Professional Education, Director, Latino Diabetes Initiative, Joslin Diabetes Center, is a consultant and on the speakers bureau and scientific advisory board for Amylin Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., and Eli Lilly and Company.
 
Dr. Jerry Cavallerano, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
 
Anne E. Goebel-Fabbri, Psychologist, Behavioral and Mental Health Unit, Joslin Diabetes Center, has no relevant financial relationships.
 
Dr. Osama Hamdy,*** Medical Director, Obesity Clinical Program, Joslin Diabetes Center, is a consultant for Abbott Nutrition and Merck & Co., Inc.
 
Karen J. Kuc,* Assistant Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
 
James E. Neighbours,* Associate Director, Education Design, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
 
Dr. Robert C. Stanton, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships.
 
Dr. Howard A. Wolpert, Director of the Insulin Pump Program and Senior Physician, Joslin Diabetes Center is a consultant for Abbott Diabetes Care, Insulet Corporation, Novo Nordisk, Inc. and Becton, Dickinson and Company.
 
* Also a member of the Planning Committee
** Also a member of the Planning Committee and the faculty
***Also a member of the faculty
 
 
ACCREDITATION STATEMENT
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
CREDIT DESIGNATION
Joslin Diabetes Center designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
To Obtain CME Credits
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the posttest and activity evaluation.
  • Physicians who successfully complete the posttest and evaluation will receive CME credit.
  • You must score 65% or higher on the posttest to receive credit for this activity.
  • All other participants who successfully complete the posttest and evaluation will receive a certificate of participation.
     
COURSE VIEWING REQUIREMENTS
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5 and above
 
Release Date: August 13, 2013
Expiration Date: August 12, 2014
 
 
ACKNOWLEDGEMENT
This activity is sponsored by Joslin Diabetes Center.
 
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly USA; Novo Nordisk Inc, Sanofi USA, LLC.; Daiichi Sankyo Inc.
 
If you have any questions regarding this activity, send an email to profedweb@joslin.harvard.edu.
 
Copyright © 2013 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.